Suppr超能文献

中国人群高苯丙氨酸血症候选基因的突变谱及基因型-表型相关性。

Mutation spectrum of hyperphenylalaninemia candidate genes and the genotype-phenotype correlation in the Chinese population.

机构信息

Department of Pediatric Endocrinology and Genetic Metabolism, Shanghai Institute for Pediatric Research, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.

Department of Rehabilitation Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.

出版信息

Clin Chim Acta. 2018 Jun;481:132-138. doi: 10.1016/j.cca.2018.02.035. Epub 2018 Feb 28.

Abstract

BACKGROUND

Hyperphenylalaninemia (HPA) is an inherited metabolic disorder that is caused by a deficiency of phenylalanine hydroxylase (PAH) or tetrahydrobiopterin. The prevalence of HPA varies widely around the world.

METHODS

A spectrum of HPA candidate genes in 1020 Chinese HPA patients was reported. Sanger sequencing, next generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA) and quantitative real-time PCR (qRT-PCR) were applied to precisely molecular diagnose HPA patients. The allelic phenotype values (APV) and genotypic phenotype values (GPV) were calculated in PAH-deficient patients based on a recently developed formula.

RESULTS

Apart from genetic diagnoses confirmed in 915 HPA patients (89.7%) by Sanger sequencing, pathogenic variants were discovered in another 57 patients (5.6%) through deep detections (NGS, MLPA and qRT-PCR). We identified 196, 42, 10 and 2 variants in PAH, PTS, QDPR and GCH1, respectively. And a total of 47 novel variants were found in these genes. Through the APV and GPV calculations, it was found that the new GPV system was well correlated with metabolic phenotypes in most PAH-deficient patients.

CONCLUSIONS

More HPA candidate variants were identified using new molecular diagnostic methods. The new APV and GPV system is likely to be highly beneficial for predicting clinical phenotypes for PAH-deficient patients.

摘要

背景

高苯丙氨酸血症(HPA)是一种遗传性代谢紊乱,由苯丙氨酸羟化酶(PAH)或四氢生物蝶呤缺乏引起。HPA 的患病率在世界各地差异很大。

方法

报道了 1020 例中国 HPA 患者的一系列 HPA 候选基因。应用 Sanger 测序、下一代测序(NGS)、多重连接依赖性探针扩增(MLPA)和实时定量 PCR(qRT-PCR)对 HPA 患者进行精确的分子诊断。根据最近开发的公式,在 PAH 缺乏的患者中计算等位基因表型值(APV)和基因型表型值(GPV)。

结果

除了通过 Sanger 测序在 915 例 HPA 患者(89.7%)中证实的遗传诊断外,还通过深度检测(NGS、MLPA 和 qRT-PCR)在另外 57 例患者(5.6%)中发现了致病性变异。我们在 PAH、PTS、QDPR 和 GCH1 中分别鉴定了 196、42、10 和 2 个变异,共发现这些基因中的 47 个新变异。通过 APV 和 GPV 的计算,发现新的 GPV 系统与大多数 PAH 缺乏患者的代谢表型密切相关。

结论

使用新的分子诊断方法发现了更多的 HPA 候选变异。新的 APV 和 GPV 系统可能非常有助于预测 PAH 缺乏患者的临床表型。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验